Legend Biotech Announces Appointment of Chief Medical Officer
11 April 2023 - 10:30PM
Business Wire
Legend Biotech Corporation (“Legend Biotech” or the “Company”)
(NASDAQ: LEGN), a global biotechnology company developing,
manufacturing and commercializing novel therapies to treat
life-threatening diseases, today announced the appointment of
Mythili Koneru, M.D., Ph.D. as the Company’s Chief Medical Officer.
In this role, Dr. Koneru will be responsible for overseeing the
Company’s clinical development and medical affairs programs.
Dr. Koneru joins Legend Biotech from Marker Therapeutics, where
she served as Chief Medical Officer, leading the development of the
company’s cell therapies and peptide vaccines in its
immuno-oncology portfolio. Prior to her time at Marker
Therapeutics, Dr. Koneru served as Associate Vice President of
Immuno-Oncology at Eli Lilly and Company, where she focused on the
clinical development of immuno-oncology assets in the company’s
early phase oncology portfolio. Prior to Eli Lilly, Dr. Koneru was
an Oncology Fellow at Memorial Sloan-Kettering Cancer Center, where
she developed adoptive T-cell therapies in both leukemia and solid
tumor malignancies in early phase clinical trials.
“On behalf of the Company, I am pleased to welcome Dr. Koneru to
the Legend team,” said Ying Huang, CEO of Legend Biotech. “Dr.
Koneru brings a wealth of knowledge in the field of immunotherapy
and cell therapy, with extensive experience in designing
early-stage clinical trials for hematologic malignancies and solid
tumors. We look forward to her leadership and contributions to our
organization, as we continue to advance our pipeline of cell-based
therapies and bring innovative therapies to clinic.”
Dr. Koneru obtained her B.A. in Cellular and Molecular Biology
from the University of Chicago, a Ph.D. in Biomedical Research:
Tumor Immunology from New York University, and an M.D. from Robert
Wood Johnson Medical School.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to
treating, and one day curing, life-threatening diseases.
Headquartered in Somerset, New Jersey, we are developing advanced
cell therapies across a diverse array of technology platforms,
including autologous and allogeneic chimeric antigen receptor
T-cell and natural killer (NK) cell-based immunotherapy. From our
three R&D sites around the world, we apply these innovative
technologies to pursue the discovery of cutting-edge therapeutics
for patients worldwide.
Learn more at www.legendbiotech.com and follow us on Twitter and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230411005132/en/
Investor Contacts: Joanne Choi, Senior Manager, Investor
Relations, Legend Biotech joanne.choi@legendbiotech.com
Crystal Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com
Press Contact: Tina Carter, Corporate Communications
Lead, Legend Biotech tina.carter@legendbiotech.com (908)
331-5025
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Apr 2024 to May 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From May 2023 to May 2024